The United States is facing an attention-deficit/hyperactivity disorder (ADHD) crisis with issues arising out of the great demand for first-line pharmacotherapy amid widespread shortages. Concerns about overmedication, particularly in children and young adults, qualify the necessity of strategic industry regulations and practices. Enforcing a balance of proper access and production of ADHD pharmacotherapy while mitigating risks of substance abuse in this line of drug treatment is vital to the health and well-being of the public.
More than 3.4 million children are currently prescribed ADHD medications, leading to federal concern about overmedication for chronic conditions in pediatric populations. Further, the American Psychiatric Association reported that adult ADHD diagnoses rose annually from 2020 to 2023, adding additional pressure to a strained healthcare infrastructure.
Pharmacy supply shortages have resulted in patients often driving long distances to pick up their prescription, particularly impacting rural and underserved communities. Lacking medication as prescribed leads to patients experiencing detriments in managing their daily life, and severe physical and mental withdrawal symptoms.
Despite these robust demands, patients are facing widespread prescription treatment shortages. As of late 2025, the Drug Enforcement Agency (DEA) has acknowledged that the existing national inventory of Schedule II substances, including d-amphetamine and methylphenidate, is inadequate to meet “legitimate patient needs.” In response, the DEA increased the Aggregate Production Quotas (APQs) for these active ingredients of first-line ADHD treatments for 2025. This action allows manufacturers to increase production and pharmacies to increase inventory, better meeting medication demand.
The DEA is responsible for enforcing regulations governing ADHD medication dispensing under the Controlled Substances Act (CSA). Stimulant medications containing the active ingredients falling under the APQ increase are typically recognized by their brand names of Adderall, Vyvanse, Concerta, and Ritalin. These medications are allocated to the Schedule II class for their associated risks with “misuse, addiction, overdose, and diversion.”
Limitations to the authority of the DEA in addressing the stimulant pharmacotherapy access crisis intersect with the market. Despite the DEA increasing the quota, the inventory of this class of products is not expanding to the capacity allocated for production. An analysis by the DEA in 2022 found that manufacturers sold only 70 percent of the volume allocated by the quota, excluding one billion additional doses from production that could have gone to the market.
In another study between 2001 and 2023 analyzing derivatives for prescription amphetamine shortages, 58 percent of manufacturers did not disclose a reason for the shortage. Other manufacturers reporting on the shortage have cited a mismatch in supply and demand, and manufacturing problems and delays.
Anticompetitive actions by manufacturers have also created structural barriers to market access. The class action Barbara et al. v. Shire brought forth allegations that brand-name manufacturers were paying rival drug makers to delay releasing generic versions of Adderall XR. This lawsuit exposed violations of the Sherman Act which bans monopolies and unreasonable trade restraints, risking supply shortages and price inflation.
The DEA works in conjunction with the FDA to regulate prescription stimulants. Recognizing the supply issues with the drugs, the two agencies issued a letter asserting their intention to understand, prevent, and reduce the impact of the shortages in pharmaceutical supply chains. However, neither agency manufactures drugs nor can they require pharmaceutical companies to increase production. While recognizing the importance of responsible prescribing practices, the agencies have called on pharmaceutical manufacturers to increase production to meet the quotas and help mitigate the stimulant drug shortage crisis the United States is facing.
